Literature DB >> 18028187

Valproic acid treatment in six patients with spinal muscular atrophy.

L-K Tsai, C-C Yang, W-L Hwu, H Li.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18028187     DOI： 10.1111/j.1468-1331.2007.01992.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  19 in total

Review 1.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

2.  Development of histone deacetylase inhibitors as therapeutics for neurological disease.

Authors:  Joel M Gottesfeld; Massimo Pandolfo
Journal:  Future Neurol       Date:  2009-11-01

3.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

4.  Modulation of synaptic transmission and analysis of neuroprotective effects of valproic Acid and derivates in rat embryonic motoneurons.

Authors:  D Ragancokova; Y Song; H Nau; R Dengler; K Krampfl; S Petri
Journal:  Cell Mol Neurobiol       Date:  2010-04-27       Impact factor: 5.046

5.  Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.

Authors:  Abdelrahman Elshafay; Truong Hong Hieu; Mohamed Fahmy Doheim; Mahmoud Attia Mohamed Kassem; Mohammed Fathi ELdoadoa; Sarah Keturah Holloway; Heba Abo-Elghar; Kenji Hirayama; Nguyen Tien Huy
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 6.  Stem cell model of spinal muscular atrophy.

Authors:  Allison D Ebert; Clive N Svendsen
Journal:  Arch Neurol       Date:  2010-06

Review 7.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

8.  SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Thomas O Crawford; Louise R Simard; Sandra P Reyna; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan L Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; John T Kissel
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

9.  SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy.

Authors:  John T Kissel; Bakri Elsheikh; Wendy M King; Miriam Freimer; Charles B Scott; Stephen J Kolb; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2014-02       Impact factor: 3.217

10.  Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice.

Authors:  Li-Kai Tsai; Ming-Shiun Tsai; Chen-Hung Ting; Hung Li
Journal:  J Mol Med (Berl)       Date:  2008-07-23       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.